1. Home
  2. WETH vs LPCN Comparison

WETH vs LPCN Comparison

Compare WETH & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WETH

Wetouch Technology Inc.

N/A

Current Price

$0.81

Market Cap

16.9M

Sector

N/A

ML Signal

N/A

Logo Lipocine Inc.

LPCN

Lipocine Inc.

N/A

Current Price

$1.60

Market Cap

18.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WETH
LPCN
Founded
1992
1997
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9M
18.7M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
WETH
LPCN
Price
$0.81
$1.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.00
AVG Volume (30 Days)
78.0K
★ 265.0K
Earning Date
11-20-2026
11-05-2026
Dividend Yield
★ 4.87%
N/A
EPS Growth
★ 15.38
N/A
EPS
★ 0.50
N/A
Revenue
★ $45,136,818.00
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.02
P/E Ratio
$1.63
★ N/A
Revenue Growth
★ 6.76
N/A
52 Week Low
$0.72
$1.36
52 Week High
$2.97
$12.37

Technical Indicators

Market Signals
Indicator
WETH
LPCN
Relative Strength Index (RSI) 37.37 46.80
Support Level N/A $1.36
Resistance Level $1.03 $2.50
Average True Range (ATR) 0.09 0.10
MACD -0.01 0.04
Stochastic Oscillator 32.37 63.16

Price Performance

Historical Comparison
WETH
LPCN

About WETH Wetouch Technology Inc.

Wetouch Technology Inc is a business of research and development, manufacturing, and distribution of touchscreen displays to customers both in the PRC and overseas. The touchscreen products, which are manufactured by the Company, are mainly for use in financial terminals, automotive, Point of Sales, gaming, lottery, medical, Human-Machine Interface (HMI), and other specialized industries. The company sells touchscreen products both domestically in China and internationally, covering areas in Mainland China, including but not limited to the eastern, southern, northern, and southwest regions of Mainland China, Taiwan, South Korea, Germany, and other countries.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: